Macrocyclic peptides to decrease c-myc protein levels and reduce cancer cell growth

Abstract

The present technology provides methods and medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] to a subject suffering from prostate cancer or breast cancer.

1 . A method comprising administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] or a pharmaceutically acceptable salt thereof to a subject suffering from prostate cancer or breast cancer. 
     
     
         2 . The method of  claim 1 , wherein the method comprises administering an effective amount of at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] or a pharmaceutically acceptable salt thereof to the subject, wherein the effective amount is effective in treating the prostate cancer or the breast cancer. 
     
     
         3 . The method of  claim 1 , wherein the prostate cancer comprises at least one oncogenic mutation found in a PC-3 cell line, a LNCaP cell line, a 22Rv1 cell line, a DU145 cell line, or a combination of any two or more thereof. 
     
     
         4 . The method of  claim 1 , wherein the breast cancer comprises triple negative breast cancer. 
     
     
         5 . The method of  claim 1 , wherein the breast cancer comprises at least one oncogenic mutation found in a BT-20 cell line, a MDA-MB-468 cell line, a MDA-MB-231 cell line, a MCF-7 cell line, a SKBR-3 cell line, a BT-474 cell ine, or a combination of any two or more thereof. 
     
     
         6 . The method of  claim 1 , wherein administering comprises oral administration or parenteral administration. 
     
     
         7 . The method of  claim 1 , wherein administering comprises at least one of subcutaneous administration, intravenous administration, and oral administration. 
     
     
         8 . The method of  claim 1 , wherein the method comprises administering cyclo[Phe-D-Pro-Phe-Trp] or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method of  claim 1 , wherein the method comprises administering cyclo[Phe-D-Pro-Phe-D-Trp] or a pharmaceutically acceptable salt thereof. 
     
     
         10 . The method of  claim 1 , wherein the method comprises administering a composition comprising at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] and a pharmaceutically acceptable carrier. 
     
     
         11 . The method of  claim 10 , wherein the composition is formulated for oral administration or parenteral administration. 
     
     
         12 . The method of  claim 10 , wherein the composition is formulated for at least one of subcutaneous administration and intravenous administration. 
     
     
         13 . The method of  claim 10 , wherein the pharmaceutically acceptable carrier comprises saline. 
     
     
         14 . The method of  claim 10 , wherein the pharmaceutically acceptable carrier comprises polyethylene glycol, a polyethylene glycol fatty acid monoester, a polyethoxylene sorbitan ester, or a combination of any two or more thereof. 
     
     
         15 . The method of  claim 10 , wherein the composition is a liquid formulation comprising about 0.1 mg/mL to about 50 mg/mL of the at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] or a pharmaceutically acceptable salt thereof. 
     
     
         16 . (canceled) 
     
     
         17 . The method of  claim 1 , wherein the method comprises administering to the subject about 1 mg to about 150 mg of the at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo [Phe-D-Pro-Phe-D-Trp] per kilogram of the subject. 
     
     
         18 . The method of  claim 1 , wherein the method comprises administering to the subject from about 1 to about 7 times per week. 
     
     
         19 .- 22 . (canceled) 
     
     
         23 . The method of  claim 2 , wherein the prostate cancer comprises at least one oncogenic mutation found in a PC-3 cell line, a LNCaP cell line, a 22Rv1 cell line, a DU145 cell line, or a combination of any two or more thereof. 
     
     
         24 . The method of  claim 2 , wherein the breast cancer comprises triple negative breast cancer. 
     
     
         25 . The method of  claim 2 , wherein the breast cancer comprises at least one oncogenic mutation found in a BT-20 cell line, a MDA-MB-468 cell line, a MDA-MB-231 cell line, a MCF-7 cell line, a SKBR-3 cell line, a BT-474 cell ine, or a combination of any two or more thereof.